IONIS PHARMACEUTICALS INC
IONIS PHARMACEUTICALS INC (IONS): 20 pipeline candidates · 15 upcoming catalysts · ~7 mo cash runway · 36 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
6.5 months
D/E 6.02 · 0% dilution
Lead: Approved
20 candidates
15 upcoming, next in ~44d
0 buys · 83 sells (180d)
A transparent, data-derived signal for IONIS PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.1B
Cash
$173.4M
Quarterly Burn
$792.8M
Runway
6.5 mo
Revenue
$246.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (20 candidates)
| Drug | Phase |
|---|---|
| bepirovirsen | Phase 2 |
| biib094 | Phase 1 |
| DAWNZERA™ (donidalorsen) | Approved |
| donidalorsen | Phase 2 |
| eplontersen | Phase 3 |
| ion269 | Phase 1 |
| ion337 | Phase 1/Phase 2 |
| ion356 | Phase 1 |
| ion363 | Phase 3 |
| ion440 | Phase 1/Phase 2 |
Showing 10 of 20 candidates. Sign up for full pipeline.
Upcoming Catalysts (15)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Binary FDA approval decision — outcome can sharply revalue the stock.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
492
Total value held
$11.35B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 24,556,637 | $1.84B |
| vanguard capital management llc | 14,236,660 | $1.07B |
| blackrock, inc. | 10,442,476 | $784.1M |
| vanguard portfolio management llc | 7,808,902 | $586.4M |
| wellington management group llp | 6,391,816 | $480.0M |
| two sigma investments, lp | 5,857,629 | $439.8M |
| geode capital management, llc | 3,984,332 | $305.2M |
| state street corp | 3,995,564 | $300.0M |
| royal bank of canada | 3,801,815 | $285.5M |
| jpmorgan chase & co | 2,363,567 | $171.4M |
Showing top 10 of 492 institutional holders of IONIS PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IONIS PHARMACEUTICALS INC's pipeline?
IONIS PHARMACEUTICALS INC (IONS) has 20 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IONIS PHARMACEUTICALS INC's lead drug candidate?
IONIS PHARMACEUTICALS INC's most advanced tracked candidate is bepirovirsen (Phase 2) for Chronic hepatitis B (CHB).
What is IONIS PHARMACEUTICALS INC's next catalyst?
IONIS PHARMACEUTICALS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Sa" — expected August 1, 2026.
What is IONIS PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IONIS PHARMACEUTICALS INC has approximately 6.5 months of cash runway.
What is IONIS PHARMACEUTICALS INC's market capitalization?
IONIS PHARMACEUTICALS INC's market capitalization is approximately $12.1B.
Get the full picture on IONIS PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.